v3.24.3

Condensed Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities:
Net loss	$ (57,790)	$ (68,930)
Changes in operating assets and liabilities:
Prepaid expenses	3,850	3,690
Accounts payable	11,761	(607)
Accounts payable-related party	28,361
Accrued expense	11,053	3,740
Net cash used in operating activities	(2,765)	(62,107)
Cash flows from investing activities:
Net cash provided by investing activities
Cash flows from financing activities
Net cash provided by financing activities
Net change in cash	(2,765)	(62,107)
Cash at beginning of period	6,806	73,195
Cash at end of period	4,041	11,088
Supplemental schedule of cash flow information
Cash paid for interest
Cash paid for income tax

Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482913/230-10-50-8

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-24

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-4

Nu-Med Plus, Inc. 10-Q